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ABSTRACT
Background: Smoking and alcohol are established risk factors for several types of cancer, but the effects on biliary cancers,
comprising biliary tract cancer (BTC) and intrahepatic bile duct cancer (IHBDC), have been inconclusive.
Methods: In this population-based prospective cohort study in Japan, we investigated the association of smoking and alcohol
consumption with the risks of BTC and its subtypes and IHBDC incidence in men and women. Furthermore, the association of
smoking stratified by drinking status was investigated. The hazard ratios (HRs) and 95% confidence intervals (CIs) were
calculated using the Cox proportional hazard model.
Results: A total of 48,367 men and 54,776 women aged 40–69 years were enrolled from 1990 through 1994 and followed up for
846,417 person-years in men and 1,021,330 person-years in women until 2012, during which 246 BTC and 80 IHBDC male
cases and 227 BTC and 60 IHBDC female cases were identified. In men, smoking was significantly associated with an increased
risk of IHBDC (HR 2.25; 95% CI, 1.19–4.25 for current smokers with ≥30 pack-years compared with non-smokers), and the
risk was enhanced among regular drinkers compared with non=occasional-drinkers (HR 3.48; 95% CI, 1.41–8.61). A non-
significant increase of IHBDC risk associated with alcohol was observed. Neither smoking nor alcohol consumption was
associated with BTC risk. In women, the association of smoking and alcohol consumption with IHBDC and BTC was unclear
because current smokers and regular drinkers were very few.
Conclusion: Our findings suggest that smoking increases IHBDC risk in men, especially among regular drinkers.
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INTRODUCTION
Biliary cancers, including biliary tract cancer (BTC) and
intrahepatic bile duct cancer (IHBDC), are highly fatal
malignancies. BTC comprises gallbladder cancer (GBC), extra-
hepatic bile duct cancer (EHBDC), and ampulla of Vater cancer
(AVC). The incidence of BTC is globally rare, but relatively
higher in East Asia.1 Chronic inflammation is strongly suggested
as one of the major risk factors of BTC,2–4 although its etiology is
poorly understood due to its low incidence. IHBDC is a cancer
that arises on a bile duct within a liver and is histologically
equivalent to EHBDC. However, IHBDC is classified as primary
liver cancer (PLC) and accounts for approximately 5% of PLC
in Japan.5 Infestation with liver flukes is a main known cause of
IHBDC, and IHBDC is suggested to share some risk factors with
both HCC (eg, hepatitis virus infection, cirrhosis)6–10 and BTC
(eg, primary sclerosing cholangitis).11,12
Smoking has been well-studied and is considered causally
related to several types of cancers.13 Smoking may cause cancer
in the epithelium of the biliary tract because carcinogenic
products, such as benzopyrene, are metabolized by hepatic
microsomes and excreted to bile,14 but the association with
BTC or IHBDC risk in humans is inconclusive because the
epidemiological studies to date have been inconsistent and
retrospective in design.7,13,15,16
Alcohol has been identified as carcinogenic for several types of
cancers, including liver cancer.13,17 The association of alcohol
consumption with IHBDC risk has been inconclusive because,
although several previous studies showed positive associations,
all were retrospective studies.13 The carcinogenic effect of alcohol
consumption on the biliary tract is controversial because an anti-
carcinogenic effect caused by inhibiting cholesterol metabolism
leading to decreased gallstone formation has been suggested.18,19
A null effect of alcohol consumption on BTC has been shown
in many of the previous studies.4,15,20–23 Furthermore, alcohol
consumption may modify the effect of smoking on the liver and
biliary tract, but it is not clear if the direction of modification
is stimulating or inhibiting because ethanol may either induce
enzymes that metabolize procarcinogen to carcinogen or
enzymes that are responsible for detoxification of the produced
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carcinogen.24 The interaction in humans has not been well-
studied for biliary cancers.
Therefore, in the present study, we investigated the association
of smoking and alcohol consumption with the risks of BTC and
its subtypes and IHBDC incidence in men and women in a large-
scale, population-based prospective cohort study in Japan, with
special focus on the difference of the risks between these cancers.
Furthermore, we investigated the effect modification of alcohol
consumption on smoking.
METHODS
Study cohort and participants
The Japan Public Health Center-based Prospective Study (JPHC
Study) is a cohort study that mainly investigates non-
communicable diseases. This study comprises two cohorts,
consisting of 140,420 participants from 11 public health centers
(PHCs). The design of this study has been reported in detail
elsewhere.25 The JPHC study was approved by the Institutional
Review Board of the National Cancer Center, Tokyo, Japan.
The present study was approved by the Ethical Review Board of
Osaka University, Osaka, Japan.
Participants from one PHC area (Katsushika PHC; 7,097
participants) in Cohort I were excluded because cancer incidence
data were not collected. Participants were also excluded for the
following reasons: non-Japanese nationality (n = 51); late report
of relocation out of the study area before the start of follow-up
(n = 188); ineligibility owing to an incorrect date of birth
(n = 7); and duplicate registration (n = 10). After excluding these
ineligible participants, 106,324 participants responded to the
baseline survey (approximately 79.9% response rate). Of the
eligible responders, we excluded the participants for whom either
smoking or alcohol consumption information was missing
(n = 2,934) or date of end of follow-up was missing (n = 243),
and the participants who were diagnosed as BTC or IHBDC
before responding to the baseline survey (n = 4).
Exposure assessment
As a baseline survey, a self-administered questionnaire was
distributed in 1990 for Cohort I and in 1993–1994 for Cohort II.
The questionnaire asked about a variety of lifestyle factors,
including smoking and alcohol habits.
For smoking habits, the questionnaire asked about smoking
status (never, former, or current smoker), age at initiation, age at
cessation (former smoker only) and average number of cigarettes
smoked per day. Participants were divided into the following
four smoking groups: “never smoker”, “former smoker”, “current
smoker with <30 pack-years”, and “current smoker with “≥30
pack-years”. Pack-years, used as an indicator of smoking
intensity for current smokers, was calculated by multiplying the
years of smoking by the number of cigarettes per day divided
by 20. In the analysis for women, participants were divided in
the following two groups because female smokers were very
few: “never smoker” and “former=current smoker”.
For alcohol consumption, in Cohort I, the questionnaire asked
about frequency (<1 day=month, 1–3 days=month, 1–2 days=
week, 3–4 days=week, 5–6 day=week, or everyday), then asked
about types of beverage and average volume of daily
consumption to those who consume alcoholic beverage at least
1 day=week. In Cohort II, the questionnaire asked about drinking
status (never, former, or current drinker), then asked about
frequency (1–3 days=month, 1–2 days=week, 3–4 days=week,or
almost every day), types of beverages, and average volume of
daily consumption to former and current drinker. Participants
were divided into the following four drinking groups: “non-
drinkers (<1 day=month in Cohort I and II or former drinkers
in Cohort II)”, “occasional drinkers (1–3 days=month)”, “regular
drinkers (≥1 day=week) with <300 g=week ethanol consump-
tion”, and “regular drinkers with ≥300 g=week ethanol con-
sumption”. We followed the previous studies to calculate the
amount of ethanol.26,27 In the analysis for women, participants
were divided in the following two groups because female drinkers
were very few: “non=occasional drinker” and “regular drinker”.
The validity and reproducibility of alcohol consumption
estimated from the questionnaire by the cohort was assessed
using dietary records for 28 days. Spearman’s correlation
coefficients were 0.79 in men and 0.44 in women for validity
and 0.78 in men and 0.66 in women for reproducibility.
Mean daily alcohol consumption from the questionnaire was
comparable to the dietary record.28
Follow-up and case identification
Follow-up was conducted using information about residential
status and survival collected from the residential registers of each
municipality in the study area. Information on the cause of death
was supplemented with death certificate information, with
permission from the Ministry of Health, Labor and Welfare
(MHLW) in Japan. Death certificates were coded in accordance
with the requirements of MHLW. Of the eligible participants,
10,909 moved out of the study area, 162 were lost to follow-up,
16 withdrew from the study, and 18,286 died during the at-risk
period.
The incidence of cancer was identified mainly using two data
sources: active patient notification from major local hospitals in
the study area and population-based cancer registries. Death
certificate information was used as a supplementary information
source. The site of origin and histological cancer type were coded
using the International Classification of Diseases for Oncology,
3rd Edition, with IHBDC as C22.1, GBC as C23.9, EHBDC as
C24.0, AVC as C24.1, the overlapping sites of the biliary tract as
C24.8, and unspecified as C24.9; in the present analysis, BTC
included C23.9, C24.0, C24.1, C24.8, and C24.9. If a participant
was diagnosed as having more than one cancer out of these
biliary cancers, that with the earliest diagnosis date was used
for the analysis. The proportion of cases where incidence was
ascertained using death certificates only was 10.6% for BTC and
IHBDC, and 6.2% for all types of cancer.
Statistical analysis
The number of person-years of follow-up was calculated from the
date of the baseline survey until the end of follow-up, which was
the earliest date out of the following: date of moving out of the
study area, loss to follow-up, withdrawal from the study, death,
diagnosis of biliary cancer, or the last date of the follow-up period
(December 31, 2012). In the present study, follow-up was not
ended when the participants were diagnosed with a cancer other
than BTC and IHBDC.
Hazard ratios (HRs), 95% confidence intervals (CIs), P-trend,
and P-interaction for IHBDC and BTC and its subtypes (GBC,
EHBDC, and AVC) were estimated in men and women using the
Cox proportional hazards model with adjustment for potential
confounders. For the analysis of alcohol consumption, we
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excluded participants with a history of chronic hepatitis or
cirrhosis because these participants might change their drinking
behavior (n = 1,762).29 This multivariate analysis model was
adjusted for the following factors: age (continuous), study area (10
PHC areas), body mass index (<23, ≥23 and <25, ≥25 and <27,
≥27 kg=m2, or unknown), history of cholelithiasis (no or yes),
history of diabetes mellitus (no or yes), history of chronic hepatitis
or cirrhosis (not applicable when estimate HRs for alcohol
consumption: no or yes), Japanese tea consumption (<1, 1–2, 3–4,
≥5 cup[s]=day, or unknown), smoking (not applicable when
estimate HRs for smoking: never smokers, former smokers,
current smokers with <30 pack-years, or current smokers with
≥30 pack-years), alcohol consumption (not applicable when
estimate HRs for alcohol consumption: non-drinkers, occasional
drinkers, regular drinkers with ethanol consumption of <300
g=week, and regular drinkers with ethanol consumption of
≥300 g=week). Additionally, HRs for smoking status stratified
by drinking status (non=occasional drinkers vs regular drinkers)
were estimated.
P-trend was calculated by assigning ordinal values to each
category and entering as a continuous term in each model. P-
interaction to evaluate effect modification of alcohol consumption
(non=occasional drinkers vs regular drinker) on smoking was
calculated by assigning ordinal values to each variable and
creating interaction term by multiplying ordinal values for each
variable. All P values reported were two-sided, and the
significance level was set at P < 0.05. All statistical analyses
were performed using Stata Version 13 (Stata Corporation,
College Station, TX, USA).
RESULTS
Baseline characteristics of the participants by smoking and
alcohol consumption are shown in Table 1. A total of 103,143
participants (48,367 men and 54,776 women) were included in
the analysis population and followed up for 1,867,747 person-
years (846,417 in men and 1,021,330 in women). During the
follow-up period, 246 cases of BTC (70 GBCs, 140 EHBDCs, 26
AVCs, 10 unspecified location, and no cases of overlapping site),
and 80 cases of IHBDC were identified in men, and 227 cases
of BTC (119 GBCs, 78 EHBDCs, 16 AVCs, 14 unspecified
location, and no cases of overlapping site), and 60 cases of
IHBDC were identified in women. The proportions of smokers
and regular drinkers in women were remarkably lower than those
in men. The proportion of regular drinkers was higher among
smokers than that among never smokers, and the proportion of
current smokers was higher among regular drinkers than that
among non-=occasional drinkers in men and women.
The HRs and 95% CIs of the incidence of BTC and its
subtypes (GBC, EHBDC, and AVC) and IHBDC associated with
smoking in men are shown in Table 2. No clear association of
smoking with BTC and its subtypes was observed. A significantly
increased risk of IHBDC associated with smoking was observed
(HR 2.25; 95% CI, 1.19–4.25 for current smokers with ≥30 pack-
years compared with non-smokers, P-trend = 0.001).
The HRs and 95% CIs of the incidence of BTC and its
subtypes and IHBDC associated with alcohol consumption in
men are shown in Table 3. No clear association of alcohol
consumption with BTC and its subtypes was observed. A non-
significant trend of increased risk of IHBDC associated with
increased alcohol consumption was observed (HR 1.96; 95% CI,
0.99–3.91 for regular drinkers with ≥300 g of ethanol
consumption compared with non-drinkers, P-trend = 0.065).
The HRs and 95% CIs of the incidence of BTC and its
subtypes and IHBDC associated with smoking stratified by
drinking status (non-=occasional drinkers vs regular drinkers) in
men are shown in Table 4. Current smokers with ≥30 pack-years
had a non-significant trend of increased BTC risk compared with
Table 1. Characteristics of the study participants at baseline
Smoking status Alcohol consumption







(<30) (≥30) (<300 g) (≥300 g)
Men
Number of subjects 11,805 11,381 11,127 14,054 10,636 4,187 20,689 11,641
Person-years 213,060.1 199,244.8 196,699.2 237,413.4 181,021.0 76,850.3 363,215.8 207,917.2
Age, years, mean (SD) 51.8 (7.6) 53.3 (8.3) 48.2 (7.4) 52.6 (7.6) 53.6 (8.5) 50.2 (7.4) 51.2 (8.0) 50.7 (7.2)
BMI, kg=m2, mean (SD) 23.9 (2.8) 23.8 (2.8) 23.1 (2.8) 23.2 (2.9) 23.3 (3.0) 24.0 (3.0) 23.4 (2.7) 23.5 (2.8)
History of cholelithiasis, Yes, % 3.0 3.2 2.2 2.7 3.4 3.2 2.4 2.3
History of diabetes mellitus, Yes, % 5.8 7.3 5.6 7.5 7.5 6.1 5.8 6.4
History of chronic hepatitis or cirrhosis, Yes, % 2.0 2.8 2.4 2.8 — — — —
Japanese tea consumption, ≥1=day, % 70.1 75.4 70.3 77.2 73.4 69.3 74.9 72.2
Current smoker, % — — — — 46.9 46.7 50.2 61.7
Regular drinker, ≥1=week, % 61.2 68.6 71.6 71.3 — — — —
Never Smoker Former=Current Smoker Non=Occasional Drinker Regular Drinker
Women
Number of subjects 50,451 4,325 47,210 7,018
Person-years 947,696.6 73,633.2 886,178.5 126,431.9
Age, years, mean (SD) 52.1 (8.0) 50.0 (7.9) 52.3 (8.0) 49.1 (7.3)
BMI, kg=m2, mean (SD) 23.4 (3.1) 23.1 (3.5) 23.5 (3.2) 22.9 (3.0)
History of cholelithiasis, Yes, % 3.0 4.0 3.1 2.3
History of diabetes mellitus, Yes, % 2.9 4.0 3.1 2.1
History of chronic hepatitis or cirrhosis, Yes, % 0.9 1.8 — —
Japanese tea consumption, ≥1=day, % 75.2 69.7 74.8 74.5
Current smoker, % — — 4.6 17.3
Regular drinker, ≥1=week, % 11.0 34.8 — —
CI, confidence interval; HR, hazard ratio; IR, incidence ratio; SD, standard deviation.
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non-smokers among non-=occasional drinkers (HR 1.64; 95% CI,
0.94–2.86) but not among regular drinkers, and the interaction
was marginally significant (P-interaction = 0.023). Current
smokers had significantly increased risk of IHBDC among
regular drinkers (HR 3.57; 95% CI, 1.39–9.22 for current smokers
with <30 pack-years and HR 3.48; 95% CI, 1.41–8.61 for current
smokers with ≥30 pack-years compared with non-smokers,
P-trend = 0.001) but not among non-=occasional drinkers.
The HRs and 95% CIs of the incidence of BTC and its
subtypes and IHBDC associated with smoking and alcohol
consumption in women are shown in Table 5. AVC was not
analyzed because of the limited number of cases, and the analysis
for smoking stratified by alcohol consumption was not conducted
because female smokers and regular drinkers were too few to be
analyzed. Clear association of each of smoking and alcohol
consumption with these types of cancers was not observed in
women.
DISCUSSION
We investigated the association of smoking and alcohol
consumption with the risks of BTC and its subtypes and IHBDC
incidence in men and women in a large-scale population-based
prospective cohort study in Japan. The results showed a different
effect of smoking and alcohol consumption between IHBDC and
BTC in men; an increased risk of IHBDC was significantly
associated with smoking, especially among regular drinkers, and
tended to be associated with alcohol consumption; an increased
risk of BTC associated with smoking and alcohol consumption
was not observed in all participants, although a non-significant
trend of increased risk of BTC associated with smoking was
observed only in non-=occasional drinkers. The association of
smoking and alcohol consumption in women was unclear because
the proportion of current smokers and regular drinker was very
limited.
The strengths of the present study are its large sample size and
prospective design. Associations between BTC and alcohol
consumption=smoking have been investigated in a previous
study using data from the same cohort.4 The follow-up period was
extended by around 8 years since then, and the number of cases
has increased, which enabled the present study to perform more
detailed analysis, including stratification by drinking status,
analysis for each of the BTC subtypes, and the evaluation of
dose response with smoking intensity or alcohol volume. To our
knowledge, the sample size of the present study is the largest
among the epidemiological studies that have investigated the
association between BTC and smoking or alcohol consumption.
The present study showed a null effect of smoking on BTC,
while increased risk of IHBDC was observed in men. It is
interesting that different effects of smoking were observed
Table 2. HRs and 95% CIs of the incidence of BTC and IHBDC








Never smoker 14 6.6 1.00
Former smoker 12 6.0 0.82 0.38 1.79
Current smoker (<30 pack-years) 19 9.7 1.91 0.94 3.87
Current smoker (≥30 pack-years) 35 14.7 2.25 1.19 4.25
P-trend 0.001
BTC
Never smoker 67 31.4 1.00
Former smoker 71 35.6 0.96 0.68 1.34
Current smoker (<30 pack-years) 36 18.3 0.82 0.54 1.24




Never smoker 18 8.4 1.00
Former smoker 23 11.5 1.20 0.64 2.26
Current smoker (<30 pack-years) 10 5.1 0.89 0.41 1.97
Current smoker (≥30 pack-years) 19 8.0 0.99 0.51 1.91
P-trend 0.771
EHBDC
Never smoker 40 18.8 1.00
Former smoker 39 19.6 0.83 0.53 1.31
Current smoker (<30 pack-years) 20 10.2 0.74 0.43 1.29
Current smoker (≥30 pack-years) 41 17.3 0.83 0.53 1.29
P-trend 0.400
AVC
Never smoker 5 2.3 1.00
Former smoker 6 3.0 1.24 0.37 4.13
Current smoker (<30 pack-years) 5 2.5 1.50 0.42 5.29
Current smoker (≥30 pack-years) 10 4.2 2.09 0.70 6.27
P-trend 0.160
AVC, ampulla of Vater cancer; CI, confidence interval; BTC, biliary tract
cancer; EHBDC, extrahepatic bile duct cancer; GBC, gallbladder cancer;
HR, hazard ratio; IHBDC, intrahepatic bile duct cancer; IR, incidence ratio.
aAdjusted for age, study area, body mass index, history of cholelithiasis,
history of diabetes mellitus, history of chronic hepatitis or cirrhosis, Japanese
tea consumption, and alcohol consumption.
Table 3. HRs and 95% CIs of the incidence of BTC and IHBDC








Non drinker 13 7.2 1.00
Occasional drinker 7 9.1 1.57 0.62 3.98
Regular drinker (<300 g of ethanol) 32 8.8 1.51 0.78 2.89
Regular drinker (≥300 g of ethanol) 26 12.5 1.96 0.99 3.91
P-trend 0.065
BTC
Non drinker 61 33.7 1.00
Occasional drinker 17 22.1 0.92 0.53 1.59
Regular drinker (<300 g of ethanol) 101 27.8 1.08 0.78 1.49




Non drinker 19 10.5 1.00
Occasional drinker 6 7.8 1.01 0.40 2.57
Regular drinker (<300 g of ethanol) 30 8.3 0.93 0.52 1.67
Regular drinker (≥300 g of ethanol) 12 5.8 0.71 0.34 1.51
P-trend 0.430
EHBDC
Non drinker 35 19.3 1.00
Occasional drinker 7 9.1 0.72 0.32 1.63
Regular drinker (<300 g of ethanol) 53 14.6 1.05 0.68 1.63
Regular drinker (≥300 g of ethanol) 38 18.3 1.23 0.76 1.99
P-trend 0.362
AVC
Non drinker 7 3.9
Occasional drinker 3 3.9 1.14 0.29 4.52
Regular drinker (<300 g of ethanol) 12 3.3 1.01 0.39 2.58
Regular drinker (≥300 g of ethanol) 4 1.9 0.56 0.16 1.99
P-trend 0.462
AVC, ampulla of Vater cancer; CI, confidence interval; BTC, biliary tract
cancer; EHBDC, extrahepatic bile duct cancer; GBC, gallbladder cancer;
HR, hazard ratio; IHBDC, intrahepatic bile duct cancer; IR, incidence ratio.
aAdjusted for age, study area, body mass index, history of cholelithiasis,
history of diabetes mellitus, history of chronic hepatitis or cirrhosis, Japanese
tea consumption, and smoking.
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between IHBDC and BTC when stratified by drinking status; a
nonsignificant trend of increased risk of BTC in non-=occasional
drinkers and no association in regular drinkers, while we found
increased risk of IHBDC in regular drinkers and no association in
no=occasional drinkers. This finding may suggest that, although
smoking has the effect of increasing BTC risk, alcohol may
neutralize the smoking effect in BTC. With respect to the
interaction between alcohol and smoking, alcohol may potentially
have the dual effect of enhancing the smoking effect by inducing
enzymes (eg, CYP2E1) to metabolize procarcinogens into
carcinogens, and of neutralizing the smoking effect by inducing
enzyme systems responsible for detoxification of those produced
carcinogens.24 Our findings suggest that induction of enzymes
related to carcinogen metabolism by alcohol may differ between
organs (liver and biliary tract). Further investigation in other
cohort or case-control studies is needed to confirm our results.
Previous studies of the association between smoking and BTC
were inconsistent regardless of total BTC,4,22,23,30 GBC,16 or
EHBDC.15 Most of them were retrospective in design and did not
stratify by drinking status. There was only one study that
investigated the effects of smoking stratified by drinking status, in
which an increased risk associated with smoking was observed
only among non-drinkers,23 which is consistent with the present
study. For IHBDC, an increased risk was observed in three out
of eight previous studies, and a meta-analysis showed a non-
significant trend of increased risk (RR 1.35; 95% CI, 0.95–1.82),
although dose dependency was not investigated.7 The present
study is the first prospective assessment of the dose-response
relationship, and the result suggests that heavier smokers,
especially among regular drinkers, may have a higher risk.
The present study showed no clear association of alcohol
consumption with BTC, while a non-significant trend of increased
risk of IHBDC was observed in men. Alcohol consumption was
not associated with IHBDC risk among never smokers when
stratified by smoking status (HR 0.61; 95% CI, 0.12–3.09 for
regular drinkers with ≥300 g of ethanol consumption), suggesting
that the observed increased risk of IHBDC may be due to residual
confounding by smoking or interaction between smoking and
alcohol consumption. For IHBDC, 10 case-control studies have
investigated the association with alcohol consumption, and an
increased risk was observed in six studies.13
The present study is the first prospective study of the
association of smoking and drinking with IHBDC, and showed
the similar result of increased IHBDC risk to many of the
previous studies although it was not statistically significant due
to the limited sample size. For BTC, a null effect of alcohol
consumption has been consistently observed in the previous
epidemiological studies,4,15,20–23 with the exception of one
prospective study in Japan, in which increased risk of GBC
was observed.31 The present study is the largest study for BTC
Table 4. HRs and 95% CIs of the incidence of BTC and IHBDC according to smoking stratified by drinking status in men











Lower Upper Lower Upper
IHBDC
Never smoker 81,698.9 8 9.8 1.00 131,361.1 6 4.6 1.00
Former smoker 59,790.5 2 3.3 0.30 0.06 1.44 139,454.3 10 7.2 1.47 0.53 4.07
Current smoker (<30 pack-years) 55,076.9 2 3.6 0.48 0.10 2.31 141,622.3 17 12.0 3.57 1.39 9.22




Never smoker 81,698.9 22 26.9 1.00 131,361.1 45 34.3 1.00
Former smoker 59,790.5 23 38.5 1.11 0.61 2.02 139,454.3 48 34.4 0.87 0.58 1.32
Current smoker (<30 pack-years) 55,076.9 6 10.9 0.60 0.24 1.49 141,622.3 30 21.2 0.85 0.53 1.36





Never smoker 81,698.9 6 7.3 1.00 131,361.1 12 9.1 1.00
Former smoker 59,790.5 8 13.4 1.48 0.50 4.35 139,454.3 15 10.8 1.03 0.48 2.23
Current smoker (<30 pack-years) 55,076.9 0 0 0 — — 141,622.3 10 7.1 1.06 0.45 2.52




Never smoker 81,698.9 14 17.1 1.00 131,361.1 26 19.8 1.00
Former smoker 59,790.5 12 20.1 0.89 0.40 1.94 139,454.3 27 19.4 0.81 0.47 1.39
Current smoker (<30 pack-years) 55,076.9 5 9.1 0.75 0.27 2.11 141,622.3 15 10.6 0.71 0.37 1.36
Current smoker (≥30 pack-years) 68,467.6 15 21.9 1.15 0.55 2.41 168,945.8 26 15.4 0.68 0.39 1.19
P-trend 0.734 0.178
P-interaction 0.347
BTC, biliary tract cancer; CI, confidence interval; EHBDC, extrahepatic bile duct cancer; GBC, gallbladder cancer; HR, hazard ratio; IHBDC, intrahepatic bile
duct cancer; IR, incidence ratio.
aAdjusted for age, study area, body mass index, history of cholelithiasis, history of diabetes mellitus, history of chronic hepatitis or cirrhosis, Japanese tea
consumption, and alcohol consumption (non-drinker vs occasional drinker).
bAdjusted for age, study area, body mass index, history of cholelithiasis, history of diabetes mellitus, history of chronic hepatitis or cirrhosis, Japanese tea
consumption, and alcohol consumption (<300 g=week of ethanol vs ≥300 g=week of ethanol).
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and supported the result of null effect. It is not clear why a
different effect was observed between two prospective studies in
Japan, but it may be attributable to differences in the character-
istics of the study population (eg, the proportion of regular
drinkers and the amount of ethanol consumption were less in the
present study).
The present study has several limitations. First, despite the
large-scale design and sufficient sample size of total BTCs, the
sample sizes of IHBDC was limited. Second, there could be
some misclassification in the exposure category because the data
obtained at only a single point using a baseline survey for
exposure classification, and relevant changes in lifestyle during
the follow-up were not reflected in the classification. Third, there
could be some effect of unmeasured variables and residual
confounding, although the statistical model was adjusted for as
many variables as possible. For example, this study does not have
information about relevant medical history, such as anoumalous
arrangement of pancreaticobiliary duct and primary biliary
cholangitis. In addition, we did not use information on hepatitis
virus infection in this study because it is available for only one
fifth of subjects. In the future study, this information should be
collected and the multivariate model should be adjusted for these
variables. Fourth, in the present cohort, the number of female
current smokers and regular drinkers were exceedingly small,
resulting in an unclear effect of smoking and alcohol consumption
in women.
In conclusion, in a population-based, prospective cohort study
in Japan, smoking was significantly associated with an increased
risk of IHBDC in men, especially among regular drinkers. On
the other hand, smoking and alcohol consumption were not
associated with BTC risk.
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Table 5. HRs and 95% CIs of the incidence of BTC and IHBDC










Never smoker 57 6.0 1.00
Former=Current smoker 3 4.1 0.99 0.30 3.20
BTC
Never smoker 213 22.5 1.00
Former=Current smoker 14 19.0 1.16 0.67 2.01
Subtypes of BTC
GBC
Never smoker 111 11.7 1.00
Former=Current smoker 8 10.9 1.30 0.62 2.70
EHBDC
Never smoker 72 7.6 1.00
Former=Current smoker 6 8.1 1.46 0.62 3.44
Alcohol
IHBDC
Non=Occasional drinker 56 6.3 1.00
Regular drinker 2 1.6 0.43 0.10 1.79
BTC
Non=Occasional drinker 206 23.2 1.00
Regular drinker 20 15.8 1.02 0.63 1.63
Subtypes of BTC
GBC
Non=Occasional drinker 111 12.5 1.00
Regular drinker 8 6.3 0.70 0.34 1.46
EHBDC
Non=Occasional drinker 69 7.8 1.00
Regular drinker 9 7.1 1.34 0.65 2.76
BTC, biliary tract cancer; CI, confidence interval; EHBDC, extrahepatic
bile duct cancer; GBC, gallbladder cancer; HR, hazard ratio; IHBDC,
intrahepatic bile duct cancer; IR, incidence ratio.
aAdjusted for age, study area, body mass index, history of cholelithiasis,
history of diabetes mellitus, history of chronic hepatitis or cirrhosis, Japanese
tea consumption, smoking (not applicable to the analysis for smoking) and
alcohol consumption (not applicable to the analysis for alcohol).
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